PMC:7402624 / 7097-7508 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T34","span":{"begin":286,"end":292},"obj":"Body_part"}],"attributes":[{"id":"A34","pred":"fma_id","subj":"T34","obj":"http://purl.org/sig/ont/fma/fma7203"}],"text":"horts overlapped (Fig. 1A and fig. S1A). For COVID-19 patients, median BMI was 29 (range 16-78), and 68% were African American (table S2). Comorbidities in COVID-19 patients were dominated by cardiovascular risk factors (83% of the cohort). Nearly 20% of subjects suffered from chronic kidney disease and 18% had a previous thromboembolic event. A subset of patients (18%) were immunosuppressed, and 7% and 6% o"}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T4","span":{"begin":286,"end":292},"obj":"Body_part"}],"attributes":[{"id":"A4","pred":"uberon_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/UBERON_0002113"}],"text":"horts overlapped (Fig. 1A and fig. S1A). For COVID-19 patients, median BMI was 29 (range 16-78), and 68% were African American (table S2). Comorbidities in COVID-19 patients were dominated by cardiovascular risk factors (83% of the cohort). Nearly 20% of subjects suffered from chronic kidney disease and 18% had a previous thromboembolic event. A subset of patients (18%) were immunosuppressed, and 7% and 6% o"}

{"project":"LitCovid-PubTator","denotations":[{"id":"206","span":{"begin":54,"end":62},"obj":"Species"},{"id":"207","span":{"begin":165,"end":173},"obj":"Species"},{"id":"208","span":{"begin":358,"end":366},"obj":"Species"},{"id":"219","span":{"begin":45,"end":53},"obj":"Disease"},{"id":"220","span":{"begin":156,"end":164},"obj":"Disease"},{"id":"221","span":{"begin":278,"end":300},"obj":"Disease"},{"id":"222","span":{"begin":324,"end":338},"obj":"Disease"}],"attributes":[{"id":"A206","pred":"tao:has_database_id","subj":"206","obj":"Tax:9606"},{"id":"A207","pred":"tao:has_database_id","subj":"207","obj":"Tax:9606"},{"id":"A208","pred":"tao:has_database_id","subj":"208","obj":"Tax:9606"},{"id":"A219","pred":"tao:has_database_id","subj":"219","obj":"MESH:C000657245"},{"id":"A220","pred":"tao:has_database_id","subj":"220","obj":"MESH:C000657245"},{"id":"A221","pred":"tao:has_database_id","subj":"221","obj":"MESH:D051436"},{"id":"A222","pred":"tao:has_database_id","subj":"222","obj":"MESH:D013923"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"horts overlapped (Fig. 1A and fig. S1A). For COVID-19 patients, median BMI was 29 (range 16-78), and 68% were African American (table S2). Comorbidities in COVID-19 patients were dominated by cardiovascular risk factors (83% of the cohort). Nearly 20% of subjects suffered from chronic kidney disease and 18% had a previous thromboembolic event. A subset of patients (18%) were immunosuppressed, and 7% and 6% o"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T59","span":{"begin":45,"end":53},"obj":"Disease"},{"id":"T60","span":{"begin":156,"end":164},"obj":"Disease"},{"id":"T61","span":{"begin":278,"end":300},"obj":"Disease"},{"id":"T62","span":{"begin":286,"end":300},"obj":"Disease"}],"attributes":[{"id":"A59","pred":"mondo_id","subj":"T59","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A60","pred":"mondo_id","subj":"T60","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A61","pred":"mondo_id","subj":"T61","obj":"http://purl.obolibrary.org/obo/MONDO_0005300"},{"id":"A62","pred":"mondo_id","subj":"T62","obj":"http://purl.obolibrary.org/obo/MONDO_0001343"},{"id":"A63","pred":"mondo_id","subj":"T62","obj":"http://purl.obolibrary.org/obo/MONDO_0005240"}],"text":"horts overlapped (Fig. 1A and fig. S1A). For COVID-19 patients, median BMI was 29 (range 16-78), and 68% were African American (table S2). Comorbidities in COVID-19 patients were dominated by cardiovascular risk factors (83% of the cohort). Nearly 20% of subjects suffered from chronic kidney disease and 18% had a previous thromboembolic event. A subset of patients (18%) were immunosuppressed, and 7% and 6% o"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T74","span":{"begin":134,"end":136},"obj":"http://purl.obolibrary.org/obo/CLO_0008922"},{"id":"T75","span":{"begin":134,"end":136},"obj":"http://purl.obolibrary.org/obo/CLO_0050052"},{"id":"T76","span":{"begin":286,"end":292},"obj":"http://purl.obolibrary.org/obo/UBERON_0002113"},{"id":"T77","span":{"begin":286,"end":292},"obj":"http://www.ebi.ac.uk/efo/EFO_0000927"},{"id":"T78","span":{"begin":286,"end":292},"obj":"http://www.ebi.ac.uk/efo/EFO_0000929"},{"id":"T79","span":{"begin":305,"end":307},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T80","span":{"begin":313,"end":314},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T81","span":{"begin":346,"end":347},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T82","span":{"begin":368,"end":370},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"}],"text":"horts overlapped (Fig. 1A and fig. S1A). For COVID-19 patients, median BMI was 29 (range 16-78), and 68% were African American (table S2). Comorbidities in COVID-19 patients were dominated by cardiovascular risk factors (83% of the cohort). Nearly 20% of subjects suffered from chronic kidney disease and 18% had a previous thromboembolic event. A subset of patients (18%) were immunosuppressed, and 7% and 6% o"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T22","span":{"begin":134,"end":136},"obj":"Chemical"}],"attributes":[{"id":"A22","pred":"chebi_id","subj":"T22","obj":"http://purl.obolibrary.org/obo/CHEBI_29387"}],"text":"horts overlapped (Fig. 1A and fig. S1A). For COVID-19 patients, median BMI was 29 (range 16-78), and 68% were African American (table S2). Comorbidities in COVID-19 patients were dominated by cardiovascular risk factors (83% of the cohort). Nearly 20% of subjects suffered from chronic kidney disease and 18% had a previous thromboembolic event. A subset of patients (18%) were immunosuppressed, and 7% and 6% o"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T4","span":{"begin":278,"end":300},"obj":"Phenotype"},{"id":"T5","span":{"begin":324,"end":344},"obj":"Phenotype"}],"attributes":[{"id":"A4","pred":"hp_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/HP_0012622"},{"id":"A5","pred":"hp_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/HP_0001907"}],"text":"horts overlapped (Fig. 1A and fig. S1A). For COVID-19 patients, median BMI was 29 (range 16-78), and 68% were African American (table S2). Comorbidities in COVID-19 patients were dominated by cardiovascular risk factors (83% of the cohort). Nearly 20% of subjects suffered from chronic kidney disease and 18% had a previous thromboembolic event. A subset of patients (18%) were immunosuppressed, and 7% and 6% o"}

{"project":"LitCovid-sentences","denotations":[{"id":"T48","span":{"begin":41,"end":138},"obj":"Sentence"},{"id":"T49","span":{"begin":139,"end":240},"obj":"Sentence"},{"id":"T50","span":{"begin":241,"end":345},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"horts overlapped (Fig. 1A and fig. S1A). For COVID-19 patients, median BMI was 29 (range 16-78), and 68% were African American (table S2). Comorbidities in COVID-19 patients were dominated by cardiovascular risk factors (83% of the cohort). Nearly 20% of subjects suffered from chronic kidney disease and 18% had a previous thromboembolic event. A subset of patients (18%) were immunosuppressed, and 7% and 6% o"}